A $285M Investment Just Ignited This Rare Disease Contender

A $285 million oversubscribed investment just gave this company breathing room and serious momentum.

With a new acquisition and funding secured, its rare disease pipeline suddenly looks a lot more viable.

U.S. stocks jumped as progress in the Senate toward ending the historic government shutdown boosted investor confidence, while tech shares rebounded on strong AI-related revenue from TSMC.

Pfizer Inc. (NYSE: PFE) just dropped $10 billion to grab Metsera, and suddenly, the obesity drug arena feels a lot smaller.

The deal ends a heated chase with Novo Nordisk and pulls Pfizer straight into the spotlight of the world’s hottest pharma market.

Metsera’s pipeline could rival Lilly’s Zepbound and Novo’s Wegovy, but more importantly, it gives Pfizer something it’s been missing since the vaccine era swagger.

You can feel the company shaking off the dust and flexing again.

The Science of Reinvention

Pfizer is focused on sustainability and long-term success.. Metsera’s therapies go beyond weight loss, targeting metabolism, heart health, and longevity.

That’s the kind of innovation that builds billion-dollar franchises.

If you’re watching the sector, this is where things get exciting. You can practically hear Wall Street recalculating Pfizer’s odds of a comeback.

The Empire Regains Its Appetite

This deal marks more than a pipeline boost; it’s Pfizer reclaiming ambition. The company is trading short-term fatigue for long-term dominance, one clinical trial at a time.

And for you, it’s proof that even giants can get hungry again.

When Pfizer moves like this, you don’t just see a merger; you witness the beginning of a new era in pharmaceutical power.

Coinbase (NASDAQ: COIN) has just made a significant move, launching a new platform that allows regular investors to acquire new digital assets before they are listed on the leading exchange.

Think of it like getting concert tickets before the bots do. Only this time, it’s crypto.

Each month, one project will take center stage, and users can participate with USD Coin during a brief window.

It’s a throwback to the wild ICO era, but with grown-up guardrails like compliance, audits, and transparent allocation rules. You might actually sleep at night this time.

From Exchange to Throne

Coinbase isn’t just a place to trade anymore; it’s slowly becoming the infrastructure of crypto itself.

Custody, liquidity, fundraising, and now launchpads - it’s building the pipes and the playground at once.

That kind of control means more influence and more trust.

And if you’re paying attention, it’s also a quiet bet that regulation will favor players who act like banks, not back-alley dealers.

The Early Bird Gets the Blockchain

For you, this platform might be the closest thing to insider access without needing a venture fund badge. It’s a front-row seat to projects before they go viral.

And while the rest of the crypto world debates decentralization, Coinbase has figured out 

how to make compliance cool. You can’t change the system overnight, but you can get in line early, and Coinbase has just opened the door.

He’s been trading full-time for more than 30 years.

And there’s one tool he trusts above all others.

It’s his #1 indicator — a clear, reliable signal that’s helped him find major opportunities long before the crowd.

It’s not complicated. It’s not technical. And it’s not sold anywhere.

This is the same signal that’s guided him through every bull and bear market.

Now, for the first time, he’s giving you free access to it — along with a short guide explaining how it works.

[Get your free copy now]

Eli Lilly (NYSE: LLY) just made one of its boldest biotech plays yet, snagging a $475 million deal with MeiraGTx Holdings for an experimental gene therapy that could one day help children born without sight see light for the first time.

It’s a bet that sounds straight out of science fiction, except the science is already in motion.

The therapy, called AAV-AIPL1, works by delivering healthy copies of a critical gene directly into the retina.

It’s a one-time treatment that aims to achieve what glasses, surgery, or medication never could: restoring functional vision by correcting the blueprint itself.

The Big Pharma Glow-Up

Lilly isn’t content being “the obesity drug company” anymore.

This move pushes it deeper into gene therapy and precision medicine, where the frontier of biotech innovation is expanding faster than your screen time.

For a company already printing billions from Zepbound and Mounjaro, the pivot into rare diseases shows a hunger for legacy, not just market share.

You can almost feel it setting up the next blockbuster pipeline.

When Science Turns Personal

Some stories make headlines, while others hit home. This one feels like both. The idea that a shot of genetic code could flip a light switch in someone’s life is as wild as it is real.

Lilly isn’t just funding research; it’s chasing something that could make blindness a treatable glitch.

If that happens, you won’t just remember the drug; you’ll remember the moment science began to see people differently.

👉 Click here to get our closing report to your cell for free!

Galecto Inc [GLTO] $17.25 (+248.48%)

Galecto surged after acquiring Damora Therapeutics and securing a $285 million oversubscribed investment, boosting its pipeline targeting rare blood cancers and funding operations into 2029.

Movano Inc [MOVE] $11.91 (+44.73%)

Movano jumped after announcing a merger with AI cloud firm Corvex, granting investors early access to GPU-as-a-Service infrastructure powering next-gen AI workloads.

Cogent Biosciences Inc [COGT] $32.46 (+119.03%)

Cogent surged on impressive Phase 3 results showing its bezuclastinib combo halved disease progression risk in GIST patients, beating the current standard of care.

Motorcar Parts Amer [MPAA] $12.86 (-26.01%)

Motorcar Parts slipped despite record sales, as investors focused on declining gross margins and another quarterly net loss driven by one-time and non-cash charges.

Surgery Partners [SGRY] $16.04 (-25.40%)

Surgery Partners fell after missing both EPS and revenue estimates, with a -31.6% earnings surprise eroding confidence despite modest revenue growth.

Bitdeer Technologies Group [BTDR] $17.65 (-19.74%)

Bitdeer plunged after posting a massive Q3 loss of $1.28 per share, missing estimates by a wide margin and fueling concerns over worsening profitability.

What if you could see where the pros are focusing now?

A newly released 5-stock report uncovers the companies that analysts believe could deliver the strongest upside in 2025.

These names show strong growth, earnings acceleration, and major market catalysts that point toward potential triple-digit returns.

The opportunity window is narrow — access is free only until midnight tonight.

[Get the 5 Stocks Report Before Access Closes]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.